Literature DB >> 22052382

Alzheimer's disease clinical trials: changing the paradigm.

Jeffrey L Cummings1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22052382     DOI： 10.1007/s11920-011-0234-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  24 in total

1.  2010 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2010-03       Impact factor: 21.566

2.  Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease.

Authors:  Antón Alvarez; Ramón Cacabelos; Carolina Sanpedro; Manuel García-Fantini; Manuel Aleixandre
Journal:  Neurobiol Aging       Date:  2006-03-29       Impact factor: 4.673

3.  Low serum progranulin predicts the presence of mutations: a prospective study.

Authors:  Emma C Schofield; Glenda M Halliday; John Kwok; Clement Loy; Kay L Double; John R Hodges
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 5.  Blood-based biomarkers of microvascular pathology in Alzheimer's disease.

Authors:  Michael Ewers; Michelle M Mielke; Harald Hampel
Journal:  Exp Gerontol       Date:  2009-09-24       Impact factor: 4.032

6.  The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients.

Authors:  Jin-Moo Lee; Kaj Blennow; Niels Andreasen; Omar Laterza; Vijay Modur; Jitka Olander; Feng Gao; Matt Ohlendorf; Jack H Ladenson
Journal:  Clin Chem       Date:  2008-08-14       Impact factor: 8.327

7.  The clinical course of advanced dementia.

Authors:  Susan L Mitchell; Joan M Teno; Dan K Kiely; Michele L Shaffer; Richard N Jones; Holly G Prigerson; Ladislav Volicer; Jane L Givens; Mary Beth Hamel
Journal:  N Engl J Med       Date:  2009-10-15       Impact factor: 91.245

8.  The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology.

Authors:  James A Mortimer; David A Snowdon; William R Markesbery
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

9.  Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.

Authors:  Guo Nan Yin; Ho Won Lee; Je-Yoel Cho; Kyoungho Suk
Journal:  Brain Res       Date:  2009-02-06       Impact factor: 3.252

10.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

Authors:  Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong
Journal:  Alzheimers Res Ther       Date:  2011-01-06       Impact factor: 6.982
View more
  4 in total

1.  Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.

Authors:  Richard E Kennedy; Gary R Cutter; Lon S Schneider
Journal:  Alzheimers Dement       Date:  2013-05-25       Impact factor: 21.566

2.  Intratarget Microdosing for Deep Phenotyping of Multiple Drug Effects in the Live Brain.

Authors:  Jennifer Kim; Sebastian W Ahn; Kyle Deans; Devon Thompson; Benjamin Ferland; Prajan Divakar; Christine Dominas; Oliver Jonas
Journal:  Front Bioeng Biotechnol       Date:  2022-03-18

3.  Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need.

Authors:  C E Teunissen; Eaj Willemse
Journal:  EJIFCC       Date:  2013-02-21

4.  Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time.

Authors:  Guoqiao Wang; Richard E Kennedy; Terry E Goldberg; Mackenzie E Fowler; Gary R Cutter; Lon S Schneider
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.